SOURCE: Implant Sciences

Implant Sciences

May 17, 2011 07:00 ET

Implant Sciences Corporation Announces $1.3 Million Order in China

Systems to Be Used for Transportation Security

WILMINGTON, MA--(Marketwire - May 17, 2011) - Continuing its growth in the Chinese market, Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that it has received an order for its Quantum Sniffer™ QS-H150 explosives trace detector totaling $1.3 million. The Quantum Sniffer will be deployed for use in transportation security in southern China.

"We are very pleased with this order," stated Bruce Bower, Senior Vice President of Sales and Marketing for Implant Sciences. "The successful deployment of the QS-H150 for use in transportation security validates our technical and operational advantages. The continued selection of the Quantum Sniffer by a growing number of Chinese transportation agencies demonstrates the consistent quality and reliability of our solutions."

Glenn D. Bolduc, Implant Sciences' CEO, added, "Transportation venues around the world have been targets for terrorist attacks, from Madrid, to London, to Mumbai. As a result, transportation security spending continues to be at the forefront of government priorities. The deployment of the Quantum Sniffer into the transportation security protocols of this major Chinese city, a first for us in this municipality, represents a new market penetrated by Implant Sciences. We are very appreciative of the efforts of our in-country distributor in securing this order as we continue our efforts to expand market penetration in China."

About the Quantum Sniffer QS-H150

The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer QS-B220

The Quantum Sniffer QS-B220, launched in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact